Status Epilepticus - Pipeline Review, H1 2016

Date: February 24, 2016
Pages: 58
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: SB9393F85C6EN
Leaflet:

Download PDF Leaflet

Status Epilepticus - Pipeline Review, H1 2016

SUMMARY

Global Markets Direct’s, ‘Status Epilepticus - Pipeline Review, H1 2016’, provides an overview of the Status Epilepticus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Status Epilepticus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Status Epilepticus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Status Epilepticus
  • The report reviews pipeline therapeutics for Status Epilepticus by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Status Epilepticus therapeutics and enlists all their major and minor projects
  • The report assesses Status Epilepticus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Status Epilepticus
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Status Epilepticus
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Status Epilepticus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Status Epilepticus Overview
Therapeutics Development
Pipeline Products for Status Epilepticus - Overview
Pipeline Products for Status Epilepticus - Comparative Analysis
Status Epilepticus - Therapeutics under Development by Companies
Status Epilepticus - Therapeutics under Investigation by Universities/Institutes
Status Epilepticus - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Status Epilepticus - Products under Development by Companies
Status Epilepticus - Products under Investigation by Universities/Institutes
Status Epilepticus - Companies Involved in Therapeutics Development
Marinus Pharmaceuticals, Inc.
RODES Inc.
Sage Therapeutics, Inc.
Status Epilepticus - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMPX-0079 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fosphenytoin sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ganaxolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAGE-217 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAGE-689 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sepranolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TG-4155 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Status Epilepticus - Recent Pipeline Updates
Status Epilepticus - Dormant Projects
Status Epilepticus - Product Development Milestones
Featured News & Press Releases
Dec 15, 2015: SAGE Updates Guidance for Top-Line Results of Phase 3 STATUS Trial of SAGE-547
Dec 02, 2015: SAGE to Present Poster Presentations on SAGE-547 at the American Epilepsy Society 69th Annual Meeting
Aug 17, 2015: SAGE Announces First Patient Treated in Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus
Aug 06, 2015: SAGE Receives Special Protocol Assessment for Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus
Jun 09, 2015: SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of SAGE-547 in Postpartum Depression
May 14, 2015: SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus
Apr 22, 2015: Ligand Earns Milestone from SAGE Therapeutics for SAGE-547
Apr 20, 2015: SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol to Evaluate SAGE-547 in Patients With Super-Refractory Status Epilepticus
Apr 09, 2015: SAGE Therapeutics presents preclinical data on SAGE-689 at Upcoming Scientific Conferences
Apr 09, 2015: SAGE Therapeutics presents Phase 1/2 clinical trial data on SAGE-547 at Upcoming Scientific Conferences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Status Epilepticus, H1 2016
Number of Products under Development for Status Epilepticus - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Status Epilepticus - Pipeline by Marinus Pharmaceuticals, Inc., H1 2016
Status Epilepticus - Pipeline by RODES Inc., H1 2016
Status Epilepticus - Pipeline by Sage Therapeutics, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Status Epilepticus Therapeutics - Recent Pipeline Updates, H1 2016
Status Epilepticus - Dormant Projects, H1 2016

LIST OF FIGURES

Number of Products under Development for Status Epilepticus, H1 2016
Number of Products under Development for Status Epilepticus - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

COMPANIES MENTIONED

Marinus Pharmaceuticals, Inc.
RODES Inc.
Sage Therapeutics, Inc.
Skip to top


Status Epilepticus - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 65 pages
Status Epilepticus - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Seizures - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 214 pages
Seizures - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 201 pages

Ask Your Question

Status Epilepticus - Pipeline Review, H1 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: